TargetMol

Fascaplysin chloride

Product Code:
 
TAR-T27305
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27305-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Fascaplysin is a cyclin D kinase 4/ cyclin D1 inhibitor (IC50 = 0.35 μM). Fascaplysin induces caspase mediated crosstalk between autophagy and apoptosis through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia HL-60 cells.
CAS:
114719-57-2
Formula:
C18H11ClN2O
Molecular Weight:
306.75
Purity:
0.98
SMILES:
[Cl-].O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc34)c12

References

1. Mischitelli M, Jema? M, Almasry M, Faggio C, Lang F. Triggering of Suicidal Erythrocyte Death by Fascaplysin. Cell Physiol Biochem. 2016;39(4):1638-47. doi: 10.1159/000447865. PubMed PMID: 27626793. 2. Manda S, Sharma S, Wani A, Joshi P, Kumar V, Guru SK, Bharate SS, Bhushan S, Vishwakarma RA, Kumar A, Bharate SB. Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure-activity relationship. Eur J Med Chem. 2016 Jan 1;107:1-11. doi: 10.1016/j.ejmech.2015.10.049. PubMed PMID: 26560048. 3. Ampofo E, Sp?ter T, M?ller I, Eichler H, Menger MD, Laschke MW. The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity. Mar Drugs. 2015 Nov 9;13(11):6774-91. doi: 10.3390/md13116774. PubMed PMID: 26569265; PubMed Central PMCID: PMC4663553. 4. Mahgoub T, Eustace AJ, Collins DM, Walsh N, O'Donovan N, Crown J. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma. Int J Oncol. 2015 Sep;47(3):900-8. doi: 10.3892/ijo.2015.3097. PubMed PMID: 26201960; PubMed Central PMCID: PMC4532220.